{
    "title": "Probiotic Streptococcus salivarius K12 for Reduction of Oral Malodour (Halitosis)",
    "inventor_name": "John Tagg",
    "publication_year": 2006,
    "device_name": "Streptococcus salivarius K12 lozenges",
    "goal": "Reduce oral malodour by suppressing volatile sulphur compound (VSC) production",
    "problem_addressed": "Halitosis caused by overgrowth of VSC-producing bacteria in the mouth",
    "concept_summary": "A bacteriocin-producing probiotic strain (Streptococcus salivarius K12) is administered after an antimicrobial mouthwash to colonize the oral cavity, competitively inhibit odor-causing bacteria, and thereby lower volatile sulphur compound levels.",
    "detailed_description": "Subjects with halitosis first use a chlorhexidine mouthwash to reduce the existing oral microbiota. Over the next three days they take lozenges containing either S. salivarius K12 or a placebo. VSC measurements one week later show that 85 % of the K12 group achieve >100 ppb reductions versus 30 % of the placebo group. PCR-DGGE profiling demonstrates shifts in saliva bacterial composition after K12 treatment, and in-vitro antagonism tests confirm that K12 suppresses growth of black-pigmented and other halitosis-associated bacteria. The probiotic is intended for use as a lozenge or spray to maintain a beneficial oral microbiome and prevent re-colonisation by pathogenic species.",
    "category": "Medical & Dental Technologies",
    "principles": [
        "Competitive exclusion",
        "Bacteriocin production",
        "Microbiome modulation"
    ],
    "scientific_domains": [
        "Microbiology",
        "Dentistry",
        "Oral Health",
        "Probiotics"
    ],
    "mechanisms_of_action": [
        "Colonization of oral mucosa",
        "Inhibition of pathogenic bacteria via bacteriocins",
        "Reduction of volatile sulphur compound synthesis"
    ],
    "materials": [
        "Streptococcus salivarius K12 (live bacterial culture)",
        "Lozenge excipients (sugar, binder, flavoring)"
    ],
    "energy_sources": [],
    "inputs": [
        "Chlorhexidine mouthwash",
        "K12-containing lozenges"
    ],
    "outputs": [
        "Lower VSC concentrations in breath",
        "Improved oral malodour scores"
    ],
    "claimed_performance": "85 % of K12-treated subjects achieved >100 ppb VSC reduction vs 30 % of placebo; 8/13 subjects maintained reduced VSC for >=2 weeks.",
    "experimental_evidence": "Randomised preliminary study (23 participants) with chlorhexidine wash-out followed by K12 or placebo lozenges; VSC measured by gas chromatography; PCR-DGGE and in-vitro antagonism assays performed.",
    "replication_status": "Multiple independent studies (2005, 2006, 2012) report similar antimicrobial activity and VSC reduction, but large-scale clinical trials are not yet documented.",
    "keywords": [
        "Streptococcus salivarius K12",
        "Probiotic",
        "Halitosis",
        "Oral malodour",
        "Bacteriocin",
        "Volatile sulphur compounds"
    ],
    "related_technologies": [
        "Oral probiotics",
        "Antimicrobial mouthwashes",
        "Microbiome-based therapies"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.8,
    "fringe_score": 0.1,
    "evidence_strength": 0.7,
    "risk_score": 0.1,
    "trl_estimate": 6,
    "source_urls": [
        "http://www.businessinsider.com/can-you-use-a-probiotic-to-fix-bad-breath-2015-11",
        "http://www.ncbi.nlm.nih.gov/pubmed/16553730",
        "http://www.ncbi.nlm.nih.gov/pubmed/15752094",
        "http://www.ncbi.nlm.nih.gov/pubmed/21512345"
    ],
    "organizations": [
        "New Zealand probiotic manufacturer (BLIS K12)",
        "University of North Carolina Microbiome Research Core"
    ],
    "applications": [
        "Halitosis treatment",
        "Oral health maintenance",
        "Adjunct to antimicrobial mouthwashes"
    ],
    "limitations": [
        "Efficacy may vary between individuals",
        "Requires prior antimicrobial mouthwash for optimal effect",
        "Regulatory status of probiotic supplements is limited in some regions"
    ],
    "open_questions": [
        "Duration of colonisation after cessation of lozenge use",
        "Impact on overall oral microbiome diversity",
        "Optimal dosing regimen and formulation"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "85% of the K12-treated group and 30% of the placebo group had substantial (>100 ppb) reductions in VSC levels.",
        "Changes in the PCR-DGGE profiles occurred in most subjects following K12 treatment.",
        "In vitro testing showed that S. salivarius K12 suppressed the growth of black-pigmented bacteria implicated in halitosis."
    ]
}